The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network
Open accessAbstract
Nuclear exclusion of the PTEN (phosphatase and tensin homologue deleted in chromosome 10) tumour suppressor has been associated with cancer progression. However, the mechanisms leading to this aberrant PTEN localization in human cancers are currently unknown. We have previously reported that ubiquitinylation of PTEN at specific lysine residues regulates its nuclear-cytoplasmic partitioning. Here we show that functional promyelocytic leukaemia protein (PML) nuclear bodies co-ordinate PTEN localization by opposing the action of a previously unknown PTEN-deubiquitinylating enzyme, herpesvirus-associated ubiquitin-specific protease (HAUSP, also known as USP7), and that the integrity of this molecular framework is required for PTEN to be able to enter the nucleus. We find that PTEN is aberrantly localized in acute promyelocytic leukaemia, in which PML function is disrupted by the PML-RARalpha fusion oncoprotein. Remarkably, treatment with drugs that trigger PML-RARalpha degradation, such as all-trans retinoic acid or arsenic trioxide, restore nuclear PTEN. We demonstrate that PML opposes the activity of HAUSP towards PTEN through a mechanism involving the adaptor protein DAXX (death domain-associated protein). In support of this paradigm, we show that HAUSP is overexpressed in human prostate cancer and is associated with PTEN nuclear exclusion. Thus, our results delineate a previously unknown PML-DAXX-HAUSP molecular network controlling PTEN deubiquitinylation and trafficking, which is perturbed by oncogenic cues in human cancer, in turn defining a new deubiquitinylation-dependent model for PTEN subcellular compartmentalization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The majority of HAUSP is localized in the nucleus”
From USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 (2010) · cites this paper as Song et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Sundaram, S. K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T. R., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,719
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Tenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,050
Self-citationEssential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
Self-citationStructure, dynamics and functions of promyelocytic leukaemia nuclear bodies
Bernardi, R., & Pandolfi, P. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2277 · Cited by 876
Self-citationRNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation
Tatham, M. H., Geoffroy, M., Shen, L., Plechanovová, A., Hattersley, N., Jaffray, E., Palvimo, J. J., & Hay, R. T. (2008) · Nature Cell Biology · doi:10.1038/ncb1716 · Cited by 837
Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804
PTEN: One Gene, Many Syndromes
Eng, C. (2003) · Human Mutation · doi:10.1002/humu.10257 · Cited by 787
Ubiquitination regulates PTEN nuclear import and tumor suppression
Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.040 · Cited by 748
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–546 of 546
Tumor-suppressive proteases revisited: Role in inhibiting tumor progression and metastasis
Shukla, D., Mandal, T., Saha, P., Kumar, D., Kumar, S., & Srivastava, A. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818168-3.00014-0
Thiriet, M. (2012) · Biomathematical and biomechanical modeling of the circulatory and ventilatory systems · doi:10.1007/978-1-4614-4370-4_11
USP7 regulates melanoma progression through PI3K/Akt/FOXO and AMPK PathwaysPreprint
Teichmann, A. T., Jia, J., Gao, L., Zhu, D., Wang, Q., Yin, S., Qiang, H., Wieland, H., Zhang, J., & Bao, Z. (2020) · doi:10.21203/rs.3.rs-24933/v1
USP7 (Ubiquitin-Specific Protease 7)
Basu, B., Bhattacharya, S., Saha, G., & Ghosh, M. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101812
Salmena, L. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735053166.793580825
Self-citationUSP7 (Ubiquitin-Specific Protease 7)
Basu, B., Bhattacharya, S., Saha, G., & Ghosh, M. K. (2017) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101812-1
Ortiz‐Cuaran, S., Mezquita, L., Swalduz, A., Aldea, M., Mazières, J., Léonce, C., Jovelet, C., Pradines, A., Avrillon, V., Flores, W. R. C., et al. (2023) · doi:10.1158/1078-0432.22478981
Asthana, S., Srivast, M., & Mathur, R. (2023) · Research Square · doi:10.21203/rs.3.rs-2801152/v1
Biosimilars in Prostate Cancer
Patel, P., Patel, Y. P., Patel, S. G., Patel, A. S., Ganpule, A. P., & Pandey, S. N. (2024) · Springer eBooks · doi:10.1007/978-981-97-3001-8_6
Xu, X., 张乃霞, & Shi, L. (2025) · Health and Metabolism · doi:10.53941/hm.2025.100029
Dong, X., Tong, E., Zhao, C., Sui, Y., Nie, R., Han, X., & Meng, X. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117593
Ubiquitination and Deubiquitination in Oral Squamous Cell Carcinoma: Potential Drug Targets
Chang, H., Zhao, M., Jin, X., & Ying, B. (2025) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/j.pibb.2025.0191
Cinobufagin suppresses T-ALL via USP7-Mediated inhibition of NOTCH1/PI3K signaling pathways
Wang, J., Cheng, Y., Xiang, Y., Zhang, H., Wang, C., Wang, Y., Wu, H., Cheng, S., Ye, J., & Zhang, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178373
Pan, T., Li, X., Li, Y., Tao, Z., Yao, H., Wu, Y., Chen, G., Zhang, K., Zhou, Y., & Huang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16674950
Pan, T., Li, X., Li, Y., Tao, Z., Yao, H., Wu, Y., Chen, G., Zhang, K., Zhou, Y., & Huang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16674944
Pan, T., Li, X., Li, Y., Tao, Z., Yao, H., Wu, Y., Chen, G., Zhang, K., Zhou, Y., & Huang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16674947
The Nuclear Face of PTEN : Implications in Cancer Prognosis and Targeted Therapy
Ghosh, M. K., Chakraborty, S., Karmakar, S., & BASU, M. N. (2026) · BioFactors · doi:10.1002/biof.70072
van der Laan, L., Zwart, R., Kempff, J. M., Breeuwsma, N., de la Woestijne, I. D. P., Houterman, J., Vos, N., Valenzuela, I., Purushothama, M. K., van Haelst, M. M., et al. (2026) · Stem Cell Research · doi:10.1016/j.scr.2026.103934
Lima‐Fernandes, E. (2012) · theses.fr (ABES) · doi:10.70675/dc75b7cbz5451z4999za5e5z58fe19782ff1
Identification of new regulators for PML nuclear bodies
Snollaerts, T. (2016) · theses.fr (ABES) · doi:10.70675/a97a0132zae2fz4278zad92z5e4b56df97b2
Étude du rôle du transporteur de phosphate inorganique PiT1/SLC20A1 dans l'inflammation
Koumakis, E. (2016) · theses.fr (ABES) · doi:10.70675/7bdb44faz8800z4b6dz9e92zce56d29c4f27
UHRF1 inhibitors targeting the epigenetic patterns in cancer cells
Zaayter, L. (2018) · theses.fr (ABES) · doi:10.70675/4a4918c6zeddaz48a0z9169z8a3ac83c9f2d
Interaction mechanisms of epigenetic integrator UHRF1 with TIP60 acetyltransferase
Ashraf, W. (2018) · theses.fr (ABES) · doi:10.70675/aed43e61z7014z400az8077za1bb36217ac4
Inhibition of UHRF1 protein by epigenetic partners and epi-drugs
Ahmad, T. (2019) · theses.fr (ABES) · doi:10.70675/22ce2b88z3f75z4cf2zba46z32f22041638f
Fonctions et régulations de la kinase CHK1 dans l'hématopoïèse normale et leucémique
Cartel, M. (2019) · theses.fr (ABES) · doi:10.70675/7824b06fz5467z4c2cz89c1zf5bed2a53f34
Kim, J. H., Song, M., Lee, K. W., Park, S., Han, E., Moon, A., & Song, Y. S. (2026) · Life · doi:10.3390/life16050712
Self-citationOliveira, R. I., Franco, C. H., Mano, M., Habboub, R., Eisenbarth, D., Leal, A. S., & Salvador, J. A. R. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119750
Oliveira, R. I., Franco, C. H., Mano, M., Leal, A. S., & Salvador, J. A. R. (2026) · Pharmaceuticals · doi:10.3390/ph19081219
Choi, M., & Baek, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188049
Wang, Y., & Shi, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1933967
USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival
Almuhanna, H. N. B., Hay, J., Moles, M. W., Clarke, L., Cassels, J. E., Sefcick, A., McCaig, A. M., Jørgensen, H. G., & Michie, A. M. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70350
BindingDB (2020) · UC San Diego · doi:10.7270/q2q81grx
BindingDB (2026) · UC San Diego · doi:10.7270/q2bz6bzb
UNDERSTANDING THE FUNCTION OF DYRK1A THROUGH CHARACTERIZATION OF ITS INTERACTING PROTEINS
Ananthapadmanabhan, V. (2015) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/n51j-0z89
Metadata
- Authors
- Song, M. S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, J., & Pandolfi, P. P.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Pandolfi, Pier Paolo
- Venue
- Nature
- Published
- 2008-08-20
- Volume
- 455
- Issue
- 7214
- Pages
- 813-817
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3398484
- OpenAlex
- W2162648910
- Cited by
- 548
- References
- 34
- Citations by year
- 2026: 15 · 2025: 27 · 2024: 22 · 2023: 35 · 2022: 25 · 2021: 37 · 2020: 43 · 2019: 40 · 2018: 33 · 2017: 39 · 2016: 34 · 2015: 36 · 2014: 32 · 2013: 27 · 2012: 31
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- European Molecular Biology Organization
- National Institutes of Health
- National Cancer Institute (R01CA082328, P50CA092629)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- PTEN, USP7, PML, nuclear localization, PML nuclear bodies, DAXX, PML-RARA fusion, acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, prostate cancer, tumor suppressor regulation, ubiquitination, nuclear-cytoplasmic trafficking
- MeSH terms
- Promyelocytic Leukemia Protein, Ubiquitin-Specific Peptidase 7, Animals, Cell Nucleus, Fibroblasts, Humans, Male, Nuclear Proteins, Prostatic Neoplasms, Transcription Factors, Tretinoin, Ubiquitins, Leukemia, Promyelocytic, Acute, Apoptosis, Molecular Chaperones, Active Transport, Cell Nucleus, Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, PTEN Phosphohydrolase, Mice, Ubiquitination, Co-Repressor Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
